RDY vs. SRPT, KRTX, UTHR, VTRS, CTLT, BGNE, LEGN, ASND, TEVA, and ROIV
Should you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Sarepta Therapeutics (SRPT), Karuna Therapeutics (KRTX), United Therapeutics (UTHR), Viatris (VTRS), Catalent (CTLT), BeiGene (BGNE), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), Teva Pharmaceutical Industries (TEVA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.
Sarepta Therapeutics (NASDAQ:SRPT) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
Sarepta Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.
Sarepta Therapeutics received 1110 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 75.40% of users gave Sarepta Therapeutics an outperform vote while only 58.87% of users gave Dr. Reddy's Laboratories an outperform vote.
Dr. Reddy's Laboratories has a net margin of 19.26% compared to Dr. Reddy's Laboratories' net margin of -43.11%. Sarepta Therapeutics' return on equity of 20.97% beat Dr. Reddy's Laboratories' return on equity.
Sarepta Therapeutics currently has a consensus target price of $158.38, suggesting a potential upside of 22.34%. Dr. Reddy's Laboratories has a consensus target price of $80.00, suggesting a potential upside of 9.02%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Dr. Reddy's Laboratories.
In the previous week, Sarepta Therapeutics and Sarepta Therapeutics both had 4 articles in the media. Sarepta Therapeutics' average media sentiment score of 1.43 beat Dr. Reddy's Laboratories' score of 1.22 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.
Dr. Reddy's Laboratories has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Dr. Reddy's Laboratories shares are owned by institutional investors. 7.4% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Sarepta Therapeutics beats Dr. Reddy's Laboratories on 9 of the 17 factors compared between the two stocks.
Get Dr. Reddy's Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Dr. Reddy's Laboratories Competitors List
Related Companies and Tools